Predictors of Intramyocardial Hemorrhage After Reperfused ST-Segment Elevation Myocardial Infarction

Raquel P Amier1, Ruben Y G Tijssen1, Paul F A Teunissen1

  • 1Department of Cardiology, VU University Medical Center, Amsterdam, the Netherlands.

Insights

Intramyocardial hemorrhage (IMH) occurs in over half of ST-segment elevation myocardial infarction (STEMI) patients and is linked to anterior infarction and specific treatments. IMH indicates more severe heart attacks and poorer short-term function.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Interventional Cardiology

Background:

  • Microvascular injury in myocardial infarction includes intramyocardial hemorrhage (IMH).
  • IMH presence in ST-segment elevation myocardial infarction (STEMI) correlates with worse patient prognoses.
  • Predictors for IMH occurrence post-STEMI remain poorly understood.

Purpose of the Study:

  • To determine the prevalence and extent of IMH in STEMI patients.
  • To identify clinical and periprocedural predictors associated with IMH occurrence and severity.
  • To explore the relationship between IMH and infarct characteristics.

Main Methods:

  • A multicenter observational cohort study involving 410 successfully reperfused STEMI patients.
  • Cardiovascular magnetic resonance imaging (CMR) assessed microvascular obstruction and IMH.
  • IMH presence and extent were analyzed against clinical and periprocedural variables.

Main Results:

  • 54% of STEMI patients exhibited IMH.
  • IMH presence was independently associated with anterior infarction and glycoprotein IIb/IIIa inhibitor use.
  • Extensive IMH was significantly linked to anterior infarction.
  • IMH correlated with larger infarct size, greater microvascular obstruction, and impaired left ventricular function.

Conclusions:

  • Anterior infarction and glycoprotein IIb/IIIa inhibitor treatment are predictors of IMH in STEMI.
  • Extensive IMH is specifically associated with anterior infarction.
  • IMH signifies more severe myocardial infarction and worse short-term left ventricular function.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
973
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
321
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.2K